Evaluation of Access to Screening for Post-partum Depression Via the Postnatal Interview Within 8 Weeks of Birth in Women Who Have Gave Birth at the Troyes Hospital ( DEPRESSIONPP )

NCT ID: NCT06469476

Last Updated: 2024-06-21

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

400 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-03-01

Study Completion Date

2024-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Post-partum depression is defined as a depressive disorder with onset of symptoms in the year following childbirth. Several international studies have reported a prevalence of this condition of around pathology of around 15%. Santé publique France's 2021 national perinatal survey corroborated these figures, finding a prevalence of post-partum depression in France of in France of 16.7%. It is therefore a frequent pathology that can cause complications for both mother and child.

The complications both for the mother and for the mother-child bond. Indeed, post-partum depression can lead to an increased risk of infanticide, weaker mother-child attachment, and altered parental behaviour. post-partum depression can lead to maternal suicide (the second leading cause cause of maternal mortality in France). Despite the potential seriousness of severe depression and its impact on the on the mother-child bond, just under half of those suffering from severe depression suffering from severe depression consult a healthcare professional.

Fear of being judged or stigmatised, linked to misperceptions about the episode, is one of the main obstacles to consultation.

Of being judged or stigmatised, linked to erroneous representations of the depressive episode. Given the scale of this condition, and the difficulties young mothers face in seeking help for young mothers to seek help, it is vital to screen postpartum women as widely and post-partum women as early as possible. In view of the extent of this condition and the difficulties young mothers have in seeking help for young mothers, it is vital to screen post-partum women as widely and as post-partum. With this in mind, from July 2022, a compulsory early post-natal interview has been introduced, designed to screen for postpartum depression.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Main objective: To evaluate the associated factors, in particular referral by a professional as a determinant of whether or not the 'compulsory' early interview.

Secondary objective: To assess the economic, geographical and other factors associated and other factors associated with the compulsory early postnatal interview. Type of study: Observational, retrospective study. Population: Women who gave birth at the Centre Hospitalier de Troyes from July 2022 to October 2023. Assessment criteria : To be referred or not by a health professional during the early postnatal interview. Investigation plan: Send the information note and no objection to all eligible eligible women, together with the questionnaire and a T envelope to return the completed questionnaire. Inclusion criteria The study will include adult women who have given birth at the Centre hospitalier de Troyes between July 2022 and October 2023 and agreeing to take part in the study. Non-inclusion criteria The following will not be included in the study

* minors under the age of 18
* those protected by law (guardianship, curatorship and safeguard of justice)
* patients refusing to participate in the study

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Depression, Postpartum

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

RETROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

depression post partum

visit post partum

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* The study will include adult women who have given birth at the Centre hospitalier de Troyes from July 2022 to October 2023
* and agreeing to take part in the study.


* minors under the age of 18
* those protected by law (guardianship, curatorship and safeguard of justice)
* patients refusing to take part in the study
Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Centre Hospitalier de Troyes

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Amjad KATTINI, DR

Role: PRINCIPAL_INVESTIGATOR

Centre Hospitalier de Troyes

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Centre Hospitalier de Troyes

Troyes, Grand Est, France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Stéphane Sanchez, DR

Role: CONTACT

0325497561

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Stéphane Sanchez, MD

Role: primary

0625036892

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2023-A02394-41

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.